BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Masashi Kono, Naoko Tsuji, Nobuto Ozaki, Nozomu Matsumoto, Takehisa Takaba, Naoki Okumura, Masanori Kawasaki, Takafumi Tomita, Yasuko Umehara, Satoko Taniike, Hideki Endo, Ken Ochiai, Shunji Maekura, Masatoshi Kudo. A case of psoriasis vulgaris complicated with antimitochondrial M2 antibody-positive liver dysfunction after infliximab treatmentKanzo 2015; 56(12): 655 doi: 10.2957/kanzo.56.655
2
Monia E. Werlang, Michele D. Lewis, Michael J. Bartel. Tumor Necrosis Factor Alpha Inhibitor-Induced Acute PancreatitisACG Case Reports Journal 2017; 4(1): e103 doi: 10.14309/crj.2017.103
3
Paul B. Watkins, Merrie Mosedale. Schiff's Diseases of the Liver2017; : 774 doi: 10.1002/9781119251316.ch28
4
My-Linh Tran-Minh, Paula Sousa, Marianne Maillet, Matthieu Allez, Jean-Marc Gornet. Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel diseaseWorld Journal of Hepatology 2017; 9(13): 613-626 doi: 10.4254/wjh.v9.i13.613
5
Shikib Mostamand, Shauna Schroeder, Jacqueline Schenkein, Tamir Miloh. Infliximab-Associated Immunomediated Hepatitis in Children With Inflammatory Bowel DiseaseJournal of Pediatric Gastroenterology & Nutrition 2016; 63(1): 94 doi: 10.1097/MPG.0000000000001137
6
Frederick Wong, Bashaar Al Ibrahim, Joanna Walsh, Karim Qumosani. Infliximab‐induced autoimmune hepatitis requiring liver transplantationClinical Case Reports 2019; 7(11): 2135 doi: 10.1002/ccr3.2456
7
Parth Shah, Vinay Sundaram, Einar Björnsson. Biologic and Checkpoint Inhibitor‐Induced Liver Injury: A Systematic Literature ReviewHepatology Communications 2020; 4(2): 172 doi: 10.1002/hep4.1465
8
Tomoo Nakagawa, Taku Kobayashi, Kiyohiro Nishikawa, Fumika Yamada, Satoshi Asai, Yukinori Sameshima, Yasuo Suzuki, Mamoru Watanabe, Toshifumi Hibi. Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practiceIntestinal Research 2019; 17(4): 504 doi: 10.5217/ir.2019.00030
9
Jaqueline Pereira Lana, Laís Bhering Martins, Marina Chaves de Oliveira, Zélia Menezes-Garcia, Letícia Tamie Pavia Yamada, Leda Quercia Vieira, Mauro Martins Teixeira, Adaliene Versiani Matos Ferreira. TNF and IL-18 cytokines may regulate liver fat storage under homeostasis conditionsApplied Physiology, Nutrition, and Metabolism 2016; 41(12): 1295 doi: 10.1139/apnm-2016-0265
10
Cagla Bali, Nejat Altintas, Ozlem Ozmete, Ibrahim Gelincik, Hakan Yabanoglu, Neslihan Tekin, Bulent Altinsoy, Bunyamin Cuneyt Turan, Anıs Aribogan. Protective Effect of Curcumin on Carbapenem-Resistant Escherichia coli–Induced Lung Injury in RatsInternational Surgery 2016; 101(7-8): 304 doi: 10.9738/INTSURG-D-15-00256.1
11
Phan Minh Giang, Do Thi Thao, Nguyen Thi Nga, Bui Van Trung, Duong Hong Anh, Pham Hung Viet. Evaluation of the Antioxidant, Hepatoprotective, and Anti-Inflammatory Activities of Bisresorcinol Isolated from the Trunk of Heliciopsis TerminalisPharmaceutical Chemistry Journal 2019; 53(7): 628 doi: 10.1007/s11094-019-02051-7
12
S. Cazzaniga, F. Anzengruber, M. Augustin, W.H. Boehncke, L. Borradori, C. Conrad, A. Cozzio, V. Djamei, L.E. French, M. Gilliet, P. Häusermann, K. Heidemeyer, P. Itin, A.G.A. Kolios, E. Laffitte, J.‐T. Maul, C. Mainetti, L. Naldi, A.A. Navarini, S.J. Rustenbach, D. Simon, C. Sorbe, M. Streit, N. Yawalkar. Linkage between patients’ characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registryJournal of the European Academy of Dermatology and Venereology 2019; 33(12): 2313 doi: 10.1111/jdv.15983
13
Richard Conway, John J Carey. Risk of liver disease in methotrexate treated patientsWorld Journal of Hepatology 2017; 9(26): 1092-1100 doi: 10.4254/wjh.v9.i26.1092
14
Ke-Tao Jin, Shi-Bing Wang, Xiao-Jiang Ying, Huan-Rong Lan, Jie-Qing Lv, Li-Hua Zhang, Morteza Motallebnezhad, Xiao-Zhou Mou. Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancerImmunology Letters 2020; 221: 61 doi: 10.1016/j.imlet.2020.02.008
15
Lucy Shamberg, Haleh Vaziri. Hepatotoxicity of Inflammatory Bowel Disease MedicationsJournal of Clinical Gastroenterology 2018; 52(8): 674 doi: 10.1097/MCG.0000000000001084
16
Hao Chi Zhang, Wenyi Luo, Yinghong Wang. Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximabJournal for ImmunoTherapy of Cancer 2019; 7(1) doi: 10.1186/s40425-019-0532-1
17
M Mosedale, PB Watkins. Drug-induced liver injury: Advances in mechanistic understanding that will inform risk managementClinical Pharmacology & Therapeutics 2017; 101(4): 469 doi: 10.1002/cpt.564
18
Loris Lopetuso, Giammarco Mocci, Manuela Marzo, Francesca D’Aversa, Gian Rapaccini, Luisa Guidi, Alessandro Armuzzi, Antonio Gasbarrini, Alfredo Papa. Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the LiverInternational Journal of Molecular Sciences 2018; 19(8): 2199 doi: 10.3390/ijms19082199
19
Juergen Braun, Uta Kiltz, Michael Sarholz, Frank Heldmann, Andrea Regel, Xenofon Baraliakos. Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomesExpert Review of Clinical Immunology 2015; 11(8): 935 doi: 10.1586/1744666X.2015.1052795
20
Richard Conway, Candice Low, Robert J. Coughlan, Martin J. O’Donnell, John J. Carey. Risk of liver injury among methotrexate users: A meta-analysis of randomised controlled trialsSeminars in Arthritis and Rheumatism 2015; 45(2): 156 doi: 10.1016/j.semarthrit.2015.05.003
21
Sarah Raevens, Michael B. Fallon. Potential Clinical Targets in Hepatopulmonary Syndrome: Lessons From Experimental ModelsHepatology 2018; 68(5): 2016 doi: 10.1002/hep.30079
22
Cynthia Morvillo, Katherine Vinci, Lauren Hedenschoug, Leah Mancini, Carrie Mize, Kayce Tugg, Steven Stein. Risks and Safety of Advanced Therapies and Biologics in Inflammatory Bowel DiseaseGastroenterology Nursing 2020; 43(4): E159 doi: 10.1097/SGA.0000000000000523
23
Nejat Altintas, Mustafa Erboga, Cevat Aktas, Bulent Bilir, Murat Aydin, Aysun Sengul, Zehra Ates, Birol Topcu, Ahmet Gurel. Protective Effect of Infliximab, a Tumor Necrosis Factor-Alfa Inhibitor, on Bleomycin-Induced Lung Fibrosis in RatsInflammation 2016; 39(1): 65 doi: 10.1007/s10753-015-0224-z
24
Iosune Baraibar, Ignacio Melero, Mariano Ponz-Sarvise, Eduardo Castanon. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in CancerDrug Safety 2019; 42(2): 281 doi: 10.1007/s40264-018-0774-8
25
Agazi Gebreselassie, Farshad Aduli, Charles D. Howell. Rheumatologic Diseases and the LiverClinics in Liver Disease 2019; 23(2): 247 doi: 10.1016/j.cld.2018.12.007
26
Joshua B. French, Maurizio Bonacini, Marwan Ghabril, David Foureau, Herbert L. Bonkovsky. Hepatotoxicity Associated with the Use of Anti-TNF-α AgentsDrug Safety 2016; 39(3): 199 doi: 10.1007/s40264-015-0366-9